Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable
Hugosson, Jonas ; Aus, Gunnar ; Lilja, Hans LU
; Lodding, Pär
; Pihl, Carl Gustaf
and Pileblad, Erik
(2003)
In Journal of Urology
169(5).
p.1720-1723
- Abstract
- PURPOSE: We evaluated whether biennial screening with prostate specific antigen (PSA) only is sufficient to detect prostate cancer while still curable. MATERIALS AND METHODS: In Goteborg, Sweden 9,972 men 50 to 65 years old were randomized to PSA screening. During 1995 and 1996 these men were invited for a first PSA screening and invited during 1997 and 1998 for a second screening. The screening procedure included PSA measurement in all men and in those with a PSA of 3 ng./ml. or greater also it included digital rectal examination, transrectal ultrasound and sextant biopsies. RESULTS: In the first screening 5,854 men participated and 145 cancers were detected. In the second screening 5,267 men participated and 111 cancers were detected.... (More)
- PURPOSE: We evaluated whether biennial screening with prostate specific antigen (PSA) only is sufficient to detect prostate cancer while still curable. MATERIALS AND METHODS: In Goteborg, Sweden 9,972 men 50 to 65 years old were randomized to PSA screening. During 1995 and 1996 these men were invited for a first PSA screening and invited during 1997 and 1998 for a second screening. The screening procedure included PSA measurement in all men and in those with a PSA of 3 ng./ml. or greater also it included digital rectal examination, transrectal ultrasound and sextant biopsies. RESULTS: In the first screening 5,854 men participated and 145 cancers were detected. In the second screening 5,267 men participated and 111 cancers were detected. Only 9 interval cancers were diagnosed. In the second screening 102 cancers (92%) were associated with PSA less than 10 ng./ml. Of 465 men with increased PSA and who underwent biopsy with a benign outcome in the first screening 50 had cancer at the second screening. Of 241 men in whom PSA increased between screenings 1 and 2 cancer was detected in 46. None of the 2,950 men with an initial PSA of less than 1 ng./ml. had a PSA of greater than 3 ng./ml. or interval cancer. CONCLUSIONS: In men with a PSA of less than 2 ng./ml. it seems safe to offer repeat screening after 2 years with PSA only. Men with a PSA of 2 to 3 ng./ml. or a value of greater than 3 ng./ml. with negative biopsy may be better served by a shorter screening interval. Thus, different screening intervals are implied depending on baseline PSA. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1127202
- author
- Hugosson, Jonas
; Aus, Gunnar
; Lilja, Hans
LU
; Lodding, Pär
; Pihl, Carl Gustaf
and Pileblad, Erik
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Urology
- volume
- 169
- issue
- 5
- pages
- 1720 - 1723
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:12686817
- scopus:0037404941
- ISSN
- 1527-3792
- DOI
- 10.1097/01.ju.0000061183.43229.2e
- language
- English
- LU publication?
- yes
- id
- 6336a19f-9d0a-4259-bb4d-8f234566d743 (old id 1127202)
- date added to LUP
- 2016-04-01 16:42:38
- date last changed
- 2022-01-28 21:34:05
@article{6336a19f-9d0a-4259-bb4d-8f234566d743,
abstract = {{PURPOSE: We evaluated whether biennial screening with prostate specific antigen (PSA) only is sufficient to detect prostate cancer while still curable. MATERIALS AND METHODS: In Goteborg, Sweden 9,972 men 50 to 65 years old were randomized to PSA screening. During 1995 and 1996 these men were invited for a first PSA screening and invited during 1997 and 1998 for a second screening. The screening procedure included PSA measurement in all men and in those with a PSA of 3 ng./ml. or greater also it included digital rectal examination, transrectal ultrasound and sextant biopsies. RESULTS: In the first screening 5,854 men participated and 145 cancers were detected. In the second screening 5,267 men participated and 111 cancers were detected. Only 9 interval cancers were diagnosed. In the second screening 102 cancers (92%) were associated with PSA less than 10 ng./ml. Of 465 men with increased PSA and who underwent biopsy with a benign outcome in the first screening 50 had cancer at the second screening. Of 241 men in whom PSA increased between screenings 1 and 2 cancer was detected in 46. None of the 2,950 men with an initial PSA of less than 1 ng./ml. had a PSA of greater than 3 ng./ml. or interval cancer. CONCLUSIONS: In men with a PSA of less than 2 ng./ml. it seems safe to offer repeat screening after 2 years with PSA only. Men with a PSA of 2 to 3 ng./ml. or a value of greater than 3 ng./ml. with negative biopsy may be better served by a shorter screening interval. Thus, different screening intervals are implied depending on baseline PSA.}},
author = {{Hugosson, Jonas and Aus, Gunnar and Lilja, Hans and Lodding, Pär and Pihl, Carl Gustaf and Pileblad, Erik}},
issn = {{1527-3792}},
language = {{eng}},
number = {{5}},
pages = {{1720--1723}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Journal of Urology}},
title = {{Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable}},
url = {{http://dx.doi.org/10.1097/01.ju.0000061183.43229.2e}},
doi = {{10.1097/01.ju.0000061183.43229.2e}},
volume = {{169}},
year = {{2003}},
}